1. PO-1279 PFS and recurrence patterns after CCRT with durvalumab for stage III and recurrent NSCLC. (May 2022) Authors: Kishi, N.; Matsuo, Y.; Shintani, T.; Ogura, M.; Mitsuyoshi, T.; Araki, N.; Fujii, K.; Okumura, S.; Nakamatsu, K.; Kishi, T.; Atsuta, T.; Sakamoto, T.; Otsu, S.; Katagiri, T.; Narabayashi, M.; Fujishiro, S.; Iizuka, Y.; Ozasa, H.; Mizowaki, T. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S1077 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗